Abstract | BACKGROUND AND OBJECTIVES: METHODS: In an exploratory analysis of the THALES trial, we evaluated the cumulative incidence of irreversible efficacy and safety outcomes at different time points during the 30-day treatment period. The efficacy outcome was major ischemic events defined as a composite of ischemic stroke or nonhemorrhagic death. The safety outcome was major hemorrhage defined as a composite of intracranial hemorrhage and fatal bleedings. Net clinical impact was defined as the combination of these 2 endpoints. RESULTS: This analysis included a total of 11,016 patients (5,523 in the ticagrelor- aspirin group, 5,493 in the aspirin group) with a mean age of 65 years, and 39% were women. The reduction of major ischemic events by ticagrelor occurred in the first week (4.1% vs 5.3%; absolute risk reduction 1.15%, 95% CI 0.36%-1.94%) and remained throughout the 30-day treatment period. An increase in major hemorrhage was seen during the first week and remained relatively constant in the following weeks (absolute risk increase ≈0.3%). Cumulative analysis showed that the net clinical impact favored ticagrelor- aspirin in the first week (absolute risk reduction 0.97%, 95% CI, 0.17%-1.77%) and remained constant throughout the 30 days. DISCUSSION: CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for patients with mild-moderate ischemic stroke or high-risk TIA, the ischemic benefit of ticagrelor- aspirin outweighs the risk of major hemorrhage throughout the 30-day treatment period.
|
Authors | Yongjun Wang, Yuesong Pan, Hao Li, Pierre Amarenco, Hans Denison, Scott R Evans, Anders Himmelmann, Stefan James, Mikael Knutsson, Per Ladenvall, Carlos A Molina, S Claiborne Johnston |
Journal | Neurology
(Neurology)
Vol. 99
Issue 1
Pg. e46-e54
(07 05 2022)
ISSN: 1526-632X [Electronic] United States |
PMID | 35437261
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. |
Chemical References |
- Platelet Aggregation Inhibitors
- Ticagrelor
- Aspirin
|
Topics |
- Aged
- Aspirin
(therapeutic use)
- Drug Therapy, Combination
- Female
- Hemorrhage
(chemically induced, epidemiology)
- Humans
- Ischemia
- Ischemic Attack, Transient
(chemically induced, drug therapy, epidemiology)
- Ischemic Stroke
(drug therapy, epidemiology)
- Male
- Platelet Aggregation Inhibitors
(adverse effects)
- Stroke
(drug therapy, epidemiology, prevention & control)
- Ticagrelor
(therapeutic use)
|